

Magnus Öhman Appointed Executive Chairman at Realheart

Västerås, Sweden, March 11, 2024 – Scandinavian Real Heart AB (publ.) today announces that the board of directors has appointed Magnus Öhman as executive chairman. He will thereby assume an active role in the company's day-to-day operations to develop and commercialize Realheart TAH. Christer Norström, former chairman, will remain as a member of the board.

"As we approach the clinical phase in the development of Realheart's artificial heart, we take a step closer to commercialization and therefore see a need to strengthen our operational capacity in these areas. Magnus Öhman's extensive experience in leading and developing medical technology companies is invaluable, and in his new role, he will be able to contribute further to the ongoing transformation of Realheart," says former chairman of the board of Realheart, Christer Norström.

Magnus Öhman has extensive experience in the medical technology industry. He has, among other roles, been the CEO of St. Jude Medical's Swedish subsidiary in Cardiac Rhythm Management, with over 600 employees and a turnover of approximately SEK 5 billion.

"Realheart's artificial heart has tremendous potential to address complex and extensive medical needs in today's cardiac care. In my view, Realheart is ready to take the next step forward, and I very much look forward to becoming part of the daily activities and at the same time leading the overall strategic work in my new role as executive chairman," says Realheart's newly appointed chairman, Magnus Öhman.

For more information, please contact:

Magnus Öhman, Chairman of the board
Phone: +46 (0) 73-973 7840
E-mail: magnus@ohman.eu

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide entirely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart TAH (Total Artificial Heart) is currently being evaluated in extensive preclinical models ahead of its first clinical study in patients expected to commence in 2025. Realheart TAH addresses a significant and urgent medical need – currently many people worldwide are on waiting lists for a heart transplant, and unfortunately, many patients die while waiting. In the future, artificial hearts may become an alternative to transplantation for broader groups of patients with severe heart failure. The company's stock is traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se



PRESS RELEASE

11 March 2024 21:57:00 CET

For more information, please contact:

Ina Laura Perkins, CEO

Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmj.se